ACH vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a low forward P/E of 2.25 and a Price/Sales ratio of 0.02 suggesting apparent cheapness, negative profitability metrics—including a -12.45% profit margin and -196.39% ROE—undermine valuation appeal. The company faces acute liquidity risk with a current ratio of 0.86 and a near-zero quick ratio of 0.10, while earnings have collapsed with a YoY decline of 40.5%. Although insider sentiment is neutral and analysts project a 92% upside to a $4.08 target, the deteriorating fundamentals and lack of cash flow transparency present substantial risk.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACH vs LLY: Head-to-Head Comparison
This page compares Accendra Health, Inc. (ACH) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.